ClinicalTrials.gg
CompletedNCT05176951Updated Mar 17, 2025

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

A Phase 2 interventional study of Treprostinil Palmitil and Placebo in Pulmonary Hypertension, sponsored by Insmed Incorporated. Completed at 25 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies in Hypertension, Pulmonary with a site in Germany — 21 open to participants now, 28 under way, 6 of them phase 3. Hypertension, Pulmonary · Germany.

Enrollment
72nd of 105
39 · median 86
Started
2022
with 3 others
Phase 2
36 of 150
2 open now
Registered
125th of 150
by date
Lead sponsor
4 of 150
Insmed Incorporated

Among the 150 studies in Hypertension, Pulmonary with a site in Germany, this one is the 72nd largest by enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2022, is one of 36 in phase 2, and was the 125th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

21 of the 150 studies in Hypertension, Pulmonary with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertension, Pulmonary with a site in Germany, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Treprostinil Palmitil
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females must be ≥ 18 to ≤ 80 years of age at the time of signing the form (ICF).
  • Diagnosis of pulmonary hypertension (PH) associated with interstitial lung disease (ILD) (including idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF], connective tissue disease [CTD], sarcoidosis).
  • Male and female participants must use that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Male participants:

Male participants who are not sterile, with female partners of , must be using effective contraception from Day 1 to at least 90 days after the last dose of study drug.

Male participants with women of child bearing potential (WOCBP) partner must use a condom in order to avoid potential exposure to embryo/fetus.

  • Female participants: Women must be (defined as no menses for 12 months without an alternative medical cause), surgically sterile, (ie,hysterectomy and/or bilateral salpingo-oophorectomy) or using highly effective contraception methods (ie, methods that alone or in combination achieve \<1% unintended pregnancy rates per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose of study drug.
  • Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Primary diagnosis of (COPD).
  • Allergy, or documented or to TPIP or treprostinil (TRE) or mannitol (an of the TPIP formulation).
  • Received or currently treated with riociguat, endothelin receptor antagonists, selexipag, phosphodiesterase 5 (PDE5) inhibitors and/or prostacyclin analogues within 30 days prior to Screening.
  • Started therapy with pirfenidone or nintedanib \< 90 days prior to Screening, OR, if already receiving either medication, there is a dose change within 30 days of Screening Visit.
  • Any known ventricular or supraventricular tachyarrhythmia (except for paroxysmal atrial fibrillation), and/or any symptomatic bradycardia.
  • History of heart disease including (LVEF) ≤ 40% or valvular, constrictive, or symptomatic atherosclerotic heart disease (eg, stable angina, myocardial infarction, etc).
  • Participation in a cardiopulmonary rehabilitation program within 30 days of the first Screening Visit. Participation in the maintenance program of a cardiopulmonary rehabilitation program is allowed.
  • Acutely decompensated heart failure within 30 days of Screening Visit.
  • Active and current symptomatic coronavirus disease 2019 (COVID-19) and/or previous diagnosis of moderate to severe disease, or hospitalization due to COVID-19.
  • Supplemental oxygen requirement > 10L/min at rest at Screening.
  • Exacerbation of underlying lung disease or active pulmonary or upper respiratory infection within 30 days of the first dose of study drug (may be rescreened at appropriate time).
  • Current or recent (past 30 days) lower respiratory tract infection (may be rescreened at appropriate time).
  • Any form of congenital heart disease or congenital heart defect (repaired or unrepaired) other than a patent foramen ovale.
  • History of alcohol or drug abuse within 6 months prior to Screening.
  • Current use of cigarettes (as defined by Center for Disease Control (CDC)) or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes either every day or some days.
  • Participants who currently inhale marijuana (recreational or medical).
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements, in particular with 6-minute walk test (6MWT) (eg, angina pectoris, claudication, musculoskeletal disorder, need for walking aids).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Treprostinil Palmitil

    Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.

    Drug: Treprostinil Palmitil

  • Placebo comparator
    Placebo

    Participants will be administered a placebo matching TPIP once daily.

    Drug: Placebo

Interventions

  • Oral inhalation using a capsule-based dry powder inhaler device.

    Also known as: INS1009

  • DrugPlacebo

    Oral inhalation using a capsule-based dry powder inhaler device.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience Any Number of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 140

  2. Number of Participants Who Experience Any Number of Serious Adverse Events (SAEs)

    Time frame: Up to Day 140

  3. Change from Baseline in Saturation of Peripheral Capillary Oxygenation (SpO2) Levels

    Time frame: Pre-, during, and post- 6-minute walk test (6MWT) at Baseline, Week 5, Week 10, and Week 16

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  2. Cmax of Treprostinil

    Time frame: Day 1 to Week 16

  3. Time to Maximum Plasma Concentration (Tmax) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  4. Tmax of Treprostinil

    Time frame: Day 1 to Week 16

  5. Area Under Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUCtau) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  6. AUCtau of Treprostinil

    Time frame: Day 1 to Week 16

  7. Area Under Concentration-time Curve From 0 to Infinity (AUC∞) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  8. AUC∞ of Treprostinil

    Time frame: Day 1 to Week 16

  9. Area Under Concentration-time Curve From Time 0 to Last Measurable Concentration (AUClast) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  10. AUClast of Treprostinil

    Time frame: Day 1 to Week 16

  11. Apparent Total Clearance (CL/F) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  12. CL/F of Treprostinil

    Time frame: Day 1 to Week 16

  13. Elimination Half-life (t1/2) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  14. t1/2 of Treprostinil

    Time frame: Day 1 to Week 16

  15. Apparent Volume of Distribution After Terminal Phase (Vd/F) of Treprostinil Palmitil

    Time frame: Day 1 to Week 16

  16. Vd/F of Treprostinil

    Time frame: Day 1 to Week 16

07

Study locations

25 sites
  • ARG003
    Barracas, Ciudad Autónoma De BuenosAires C1280AEB, Argentina
  • ARG001
    Rosario, Santa Fe S2013KDS, Argentina
  • ARG008
    Buenos Aires, CI094AAD, Argentina
  • AUS003
    Camperdown, New South Wales 2050, Australia
  • AUS005
    Macquarie Park, New South Wales 2109, Australia
  • BEL002
    Liège, 4000, Belgium
  • GER006
    Heidelberg, Baden-Württemberg 69126, Germany
  • GER010
    Gießen, Hessen 35392, Germany
  • GER003
    Essen, Nordrhein-Westfalen 45239, Germany
  • GER001
    Dresden, Sachsen 01307, Germany
  • GER002
    Berlin, 13125, Germany
  • GER012
    Berlin, 14050, Germany
  • GER004
    Munich, 81377, Germany
  • ITA003
    Napoli, Campania 80131, Italy
  • ITA004
    Milano, Lombardia 20123, Italy
  • ITA002
    Monza, Lombardia 20900, Italy
  • ITA001
    Palermo, Sicilia 90127, Italy
  • ESP007
    Oviedo, Asturias 33011, Spain
  • ESP003
    Palma de Mallorca, Baleares 07120, Spain
  • ESP010
    Barcelona, 08035, Spain
  • ESP005
    Barcelona, 08907, Spain
  • ESP006
    las Palmas de Gran Canaria, 35010, Spain
  • ESP009
    Santiago de Compostela, 15706, Spain
  • GBR003
    Glasgow, Lanarkshire G81 4HX, United Kingdom
  • GBR001
    Sheffield, Yorkshire S10 2JF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Mar 2024, 14 months.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Jan 4, 2022
StartActual
Dec 22, 2022
Primary completionActual
Mar 14, 2024
CompletionActual
Mar 14, 2024
Results delay requested
Mar 13, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05176951
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Dec 22, 2022
Primary completion
Mar 14, 2024
Completion
Mar 14, 2024
Last update
Mar 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil hexadecyl ester

Start the discussion